Merck KGaA raises 2026 guidance third time

Germany's Merck KGaA has raised its 2026 profit guidance for the third time this year, after stronger third-quarter sales across its three businesses and a lift from favourable currency movements. The Darmstadt-based science and technology group announced the upgrade on 12 November.
Merck now expects full-year net sales of €21.5 billion to €21.9 billion, up from €21 billion to €21.8 billion, and adjusted earnings before interest, tax, depreciation and amortisation of €6.2 billion to €6.4 billion, up from €5.9 billion to €6.3 billion. Earnings per share before one-off items are forecast at €8.30 to €8.70.
Electronics leads the third quarter
Third-quarter net sales rose 5.8 per cent to €5.6 billion, with organic growth of 5.1 per cent, while adjusted EBITDA edged up 0.8 per cent to about €1.7 billion. Electronics was the strongest division, with organic growth of 13 per cent, including a 19 per cent rise in semiconductor solutions as artificial-intelligence demand lifted sales of chip materials. Life science guidance was raised to organic growth of 6–7 per cent.
Net profit fell by about half to €450 million, but the comparison was flattered by one-off gains a year earlier. The new guidance also assumes a December contribution from the planned $11.3 billion acquisition of US firm Bio-Techne.
Warning on a key drug
Management also warned that sales of its multiple sclerosis drug Mavenclad face a steep decline in 2027, a caution that tempers the otherwise confident outlook. Morningstar reported the upgrade followed earlier increases alongside first- and second-quarter results, while Reuters put the improved outlook down to better underlying performance, currency effects and the Bio-Techne deal.